Efficacy of Levofloxacin for Experimental Aortic-Valve Endocarditis in Rabbits Infected with Viridans Group Streptococcus orStaphylococcus aureus
Authors:
- 1 November 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (11) , 2742-2746
Abstract
Levofloxacin is among the more active fluoroquinolones against streptococci and staphylococci. It is effective against moderately severe infections caused by these organisms, but its efficacy in the treatment of bacteremia and serious infections such as endocarditis is not well defined. We compared the efficacy of levofloxacin to those of standard agents in the rabbit model of aortic-valve endocarditis caused by fluoroquinolone-susceptible strains including a penicillin-susceptible strain ofStreptococcus sanguis, a penicillin-resistant strain ofStreptococcus mitis, a methicillin-resistant strain ofStaphylococcus aureus, and a methicillin-susceptible strain ofS. aureus. Levofloxacin administered intramuscularly at dosages of 20 to 40 mg/kg of body weight twice daily (b.i.d.) was completely ineffective against the penicillin-susceptible strain, with mean vegetation titers after 3 days of therapy not statistically significantly different from those for controls. Levofloxacin was no more effective than penicillin against the penicillin-resistant strain. Levofloxacin administered for 4 days at a dosage of 20 mg/kg b.i.d. was at least as effective as vancomycin administered intravenously at a dosage of 25 mg/kg b.i.d. against the methicillin-resistantS. aureusstrain and was as effective as nafcillin administered intramuscularly at 100 mg three times daily against the methicillin-susceptible strain. Emergence of resistance to levofloxacin in vitro was less likely to occur than resistance to ciprofloxacin, and resistance to levofloxacin was not observed in vivo. Levofloxacin-rifampin combinations were antagonistic in vitro and in vivo. Levofloxacin was highly effective as a single agent against experimental staphylococcal endocarditis but was surprisingly ineffective against streptococcal endocarditis, suggesting that it has a potential role as treatment for seriousS. aureusbut not viridans group streptococcal infections in humans.Keywords
This publication has 31 references indexed in Scilit:
- Trends in Bacterial Resistance to FluoroquinolonesClinical Infectious Diseases, 1997
- In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococciJournal of Antimicrobial Chemotherapy, 1996
- Comparative in vitro activity of levofloxacin and ofloxacin against Gram-positive bacteriaDiagnostic Microbiology and Infectious Disease, 1996
- The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococciDiagnostic Microbiology and Infectious Disease, 1996
- Multicenter, Phase IV evaluation of intravenous cirpfloxacin as initial therapy in patients with lower respiratory tract, urinary tract, and skin/skin structure infectionsClinical Therapeutics, 1995
- Ampicillin, Sulbactam, and Rifampin Combination Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis in RabbitsThe Journal of Infectious Diseases, 1995
- Early Resistance to Rifampin and Ciproftoxacin in the Treatment of Right-Sided Staphylococcus aureus EndocarditisThe Journal of Infectious Diseases, 1991
- Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Binding Affinity for Penicillin-Binding Protein 2a Correlates with In Activity of -Lactan Antibiotics against Methicillin-Resistant Staphylococcus aureusThe Journal of Infectious Diseases, 1990
- TREATMENT OF RIGHT-SIDED STAPHYLOCOCCUS AUREUS ENDOCARDITIS IN INTRAVENOUS DRUG USERS WITH CIPROFLOXACIN AND RIFAMPICINThe Lancet, 1989